Angion Biomedica (NasdaqGS:ANGN) - Share price, News & Analysis

ANGN fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

ANGN Stock Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases.

Rewards

Revenue is forecast to grow 50.8% per year

Risk Analysis

Earnings have declined by 18.3% per year over past 5 years

Volatile share price over the past 3 months

Does not have a meaningful market cap ($37M)

Angion Biomedica Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Angion Biomedica
Historical stock prices
Current Share Price	US$1.23
52 Week High	US$16.04
52 Week Low	US$1.08
Beta	0
1 Month Change	-20.13%
3 Month Change	-38.81%
1 Year Change	-91.60%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-92.77%

Recent News & Updates

Mar 19

We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Feb 07

Angion Biomedica: Selling At Cash Value

Angion Biomedica Corp was the fifth worst IPO of 2021, down over 80% as its lead candidate failed one Phase 3 and two Phase 2 trials. The company recently announced a pivot to its other clinical asset – a potential therapy for fibrotic diseases of the kidney and lungs. Trading at a discount to cash but with no meaningful catalysts in 2022, the recent insider buying in Angion at least merited a deeper dive. A full investment analysis follows in the paragraphs below.

Shareholder Returns

	ANGN	US Pharmaceuticals	US Market
7D	0.8%	-0.02%	-4.0%
1Y	-91.6%	13.5%	-13.2%

Return vs Industry: ANGN underperformed the US Pharmaceuticals industry which returned 11.8% over the past year.

Return vs Market: ANGN underperformed the US Market which returned -12.3% over the past year.

Price Volatility

Is ANGN's price volatile compared to industry and market?
ANGN volatility
ANGN Average Weekly Movement	16.3%
Pharmaceuticals Industry Average Movement	11.7%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: ANGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: ANGN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1998	71	Jay Venkatesan	https://www.angion.com

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program.

Angion Biomedica Fundamentals Summary

How do Angion Biomedica's earnings and revenue compare to its market cap?
ANGN fundamental statistics
Market Cap	US$36.85m
Earnings (TTM)	-US$32.13m
Revenue (TTM)	US$29.59m

1.2x

P/S Ratio

-1.1x

P/E Ratio

Is ANGN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANGN income statement (TTM)
Revenue	US$29.59m
Cost of Revenue	US$43.30m
Gross Profit	-US$13.71m
Other Expenses	US$18.42m
Earnings	-US$32.13m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.07
Gross Margin	-46.34%
Net Profit Margin	-108.57%
Debt/Equity Ratio	0.4%

How did ANGN perform over the long term?

See historical performance and comparison

Valuation

Is Angion Biomedica undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

0.55x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ANGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANGN's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ANGN is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Pharmaceuticals industry average.

PE vs Market: ANGN is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANGN's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ANGN is good value based on its Price-To-Book Ratio (0.5x) compared to the US Pharmaceuticals industry average (1.8x).

Future Growth

How is Angion Biomedica forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

50.8%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ANGN's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if ANGN's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ANGN's revenue (50.8% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: ANGN's revenue (50.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ANGN's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Angion Biomedica performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-18.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ANGN is currently unprofitable.

Growing Profit Margin: ANGN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ANGN is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.

Accelerating Growth: Unable to compare ANGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).

Return on Equity

High ROE: ANGN has a negative Return on Equity (-47.81%), as it is currently unprofitable.

Financial Health

How is Angion Biomedica's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ANGN's short term assets ($76.2M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: ANGN's short term assets ($76.2M) exceed its long term liabilities ($3.7M).

Debt to Equity History and Analysis

Debt Level: ANGN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ANGN's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ANGN has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 32.8% each year.

Dividend

What is Angion Biomedica current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANGN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANGN has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure

CEO

Jay Venkatesan (49 yo)

4yrs

Tenure

US$2,539,199

Compensation

Dr. Jay R. Venkatesan, Ph D., M.D. MBA., serves as Chairman of Angion Biomedica Corp. since January 2022 and also serves as its President since January 2019 and has been its Chief Executive Officer & Direc...

CEO Compensation Analysis

Compensation vs Market: Jay's total compensation ($USD2.54M) is above average for companies of similar size in the US market ($USD770.27K).

Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: ANGN's management team is considered experienced (2.6 years average tenure).

Board Members

Experienced Board: ANGN's board of directors are considered experienced (3.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: ANGN insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31